Dr Jane Osbourn OBE - External Non-Executive Director
Dr Jane Osbourn is VP for Research and Development and Site Leader for MedImmune in Cambridge, having joined MedImmune (formerly Cambridge Antibody Technology (CAT) and now the global biologics research and development arm of AstraZeneca) in 1993.
An expert in antibody engineering, Dr Osbourn originated several key publications and patents, and has also made a significant contribution to the discovery and development of marketed drugs (Humira and Benlysta) and more than 40 clinical candidates. She is Chair of the Board of Directors of the BioIndustry Association, a Director of Babraham Bioscience Technologies, a Director of Cambridge Enterprise and has presented at a number of parliamentary Select Committees.
Dr Osbourn was awarded an OBE in the 2019 Queen’s Birthday Honours for services to human monoclonal antibody drug research and development and biotechnology.